NKTR News and Press, Nektar Therapeutics From 02/26/24

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its fi...

2024-01-22 08:31:49 ET More on DiaMedica Therapeutics Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeutics For further details see: DiaMedica The...

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42 nd Annual J.P. Morgan H...

2023-12-29 15:30:56 ET More on Inspire Medical Systems Inspire Medical Systems: Time To Wake Up Inspire Medical Systems, Inc. (INSP) Q3 2023 Earnings Call Transcript Inspire Medical Systems, Inc. 2023 Q3 - Results - Earnings Call Presentation Inspire Medical ...

Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting PR Newswire – NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-...

2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...

2023-11-07 21:11:10 ET Nektar Therapeutics (NKTR) Q3 2023 Earnings Conference Call November 07, 2023, 05:00 PM ET Company Participants Vivian Wu - Director, IR and Corporate Affairs Howard Robin - President and CEO Jonathan Zalevsky - Chief, Research and Developm...

2023-11-07 16:19:10 ET More on Nektar Therapeutics Nektar in collaboration to evaluate non-small cell lung cancer candidate Seeking Alpha’s Quant Rating on Nektar Therapeutics Historical earnings data for Nektar Therapeutics Financial information for N...

Nektar Therapeutics Reports Third Quarter 2023 Financial Results PR Newswire SAN FRANCISCO , Nov. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023 . Cash...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...